Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform.

ABSTRACT:

Background

Socioeconomic differences in receipt of adjuvant treatment contribute to persistent disparities in breast cancer (BCA) outcomes, including survival. Adjuvant endocrine therapy (AET) substantially reduces recurrence risk and is recommended by clinical guidelines for nearly all women with hormone receptor-positive non-metastatic BCA. However, AET use among uninsured or underinsured populations has been understudied. The health reform implemented by the US state of Massachusetts in 2006 expanded health insurance coverage and increased the scope of benefits for many with coverage. This study examines changes in the initiation of AET among BCA patients in Massachusetts after the health reform.

Methods

We used Massachusetts Cancer Registry data from 2004 to 2013 for a s

SUBMITTER: Eom KY 

PROVIDER: S-EPMC8088064 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature